Table 2.

Ongoing Trials With Immunotherapy in Combination With Radiation Therapy in Bladder Cancer

Disease State, Arms	Line of Therapy	N	Phase	Identifier
Pembrolizumab (anti-PD-1) + hypofractionated RT	Metastatic; progressed after ≥1 regimen of systemic therapy	70	1	NCT02303990
Combining L19-IL2 with SABR	Patients with oligometastatic solid tumors	18	1	NCT02086721
Pembrolizumab, gemcitabine, + concurrent hypofractionated RT	Patients with muscle invasive urothelial cancer who are not candidates for or decline radical cystectomy	54	2	NCT02621151
Pembrolizumab + RT	Group A: Pembrolizumab and RT in locally advanced bladder cancer Group B: Pembrolizumab and RT in metastatic bladder cancer	34	1	NCT02560636

PD-1, programmed death 1; RT, radiation therapy; SABR, stereotactic ablative body radiotherapy.